Shire pays $50 per share for ViroPharma
Further enhancing its rare disease business, Shire PLC is paying $50 per share (a 29% premium) in cash to acquire all the outstanding stock of orphan disease firm ViroPharma Inc., valuing the transaction at $3.3bn.
- Specialty Pharmaceuticals
- Large Molecule
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.